Sign In
Buy JNJ
$244.88
+3.88 (+1.61%)
At Close: Jun 25, 2026
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
10:32am, Wednesday, 13'th Dec 2023
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Economic Safety Nets: 7 Defensive Stocks Providing Portfolio Stability
08:44am, Wednesday, 13'th Dec 2023
Although investors have some evidence of a possible economic recovery, they should still consider defensive stock picks. We just don't know what will happen next.
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
04:15pm, Monday, 11'th Dec 2023
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, January 23rd to review fourth-quarter results. Joa
How To Invest $100,000 Today In A Sleep Well Portfolio
09:00am, Saturday, 09'th Dec 2023
The economic cycles have always been with us. But the frequency of boom and bust cycles has certainly increased in the last couple of decades. If the volatility of the stock market keeps you awake at
The 4 Key Qualities Of Dividend Stocks That You Can Retire On
05:00pm, Friday, 08'th Dec 2023
Dividend stocks can set you up for a wonderful, financially stress-free retirement. We discuss the four essential qualities that a dividend stock must have to make it a worthy holding in your passive
7 Tech Stocks to Light Up Your Portfolio This Holiday Season
07:30am, Friday, 08'th Dec 2023
As the festive season rolls in, finding the best tech stocks to buy is exciting, lighting up various sectors with innovative energy. These industry giants are showing impressive resilience and growth
My Top 10 High Dividend Yield Companies For December 2023
06:00pm, Thursday, 07'th Dec 2023
High dividend yield companies can provide investors with several benefits, such as the generation of income and the reduction of portfolio volatility. Furthermore, the companies' continuous dividend p
Investing in the Aging Population: 3 Healthcare Stocks to Watch
01:53pm, Thursday, 07'th Dec 2023
In 2016, there were 49 million Americans aged 65 or older. Analysts forecast that will grow to 73 million retirement-age Americans in 2030 and an eye-opening 95 million in the year 2060.
J&J (JNJ) Announces 2024 and Long-Term Financial Outlook
12:48pm, Wednesday, 06'th Dec 2023
J&J (JNJ) expects operational sales growth in the range of 5-6% in 2024, driven by both its Innovative Medicine and MedTech divisions.
How To Live Off Of Dividends For Potentially Life-Changing Passive Income
08:35am, Wednesday, 06'th Dec 2023
Living off of dividends can be truly life-changing. We discuss why and how to do this. We also share a sample portfolio for making this dream a reality.
Johnson & Johnson (JNJ) Sees a More Significant Dip Than Broader Market: Some Facts to Know
06:47pm, Tuesday, 05'th Dec 2023
In the latest trading session, Johnson & Johnson (JNJ) closed at $158.55, marking a -0.21% move from the previous day.
J&J says it has settled some talc claims, will continue bankruptcy strategy
06:23pm, Tuesday, 05'th Dec 2023
Johnson & Johnson's worldwide vice president for litigation said on Tuesday that the company has recently reached settlements with several law firms over their clients' claims that J&J talc products c
Is Buffett Turning Bearish? 7 Stocks Warren Completely Dumped in Q3
05:40pm, Tuesday, 05'th Dec 2023
Warren Buffett wrote an op-ed for The New York Times during the financial markets collapse in 2008 titled, “ Buy American. I Am. ” At the time, the housing market was in free fall, Lehman Brothe
StemPoint's Michelle Ross is bullish on J&J after stronger guidance
05:28pm, Tuesday, 05'th Dec 2023
Michelle Ross, StemPoint Capital CIO, joins 'Closing Bell' to discuss biotech, weight-loss drugs and her playbook.
J&J forecasts 2024 sales growth of up to 6%
11:54am, Tuesday, 05'th Dec 2023
Johnson & Johnson (NYSE:JNJ) said Tuesday that it expects its 2024 operation sales growth to grow between 5% and 6% as its psoriasis drug Stelara faces competition in the United States. Ahead of a mee
